TPST

+ Watchlist + Portfolio

Tempest Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.07
52-Week Range: $0.84 – $12.23
Market Cap: $16.30M
P/E (TTM): —
EPS (TTM): -3.68
Dividend Yield: —

Advanced Metrics

Price/Book: 17.89
PEG Ratio: —
Return on Equity: -931.14%
Return on Assets: -67.64%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.38
Debt/Equity: —
Total Debt: $7.56M
Free Cash Flow: $-11.14M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $23.88M

TPST Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$22.53M	$17.50M	$28.48M	$12.61M
Selling, General & Admin	$12.11M	$11.66M	$13.55M	$13.97M
Operating Expenses	$34.64M	$29.16M	$42.03M	$26.57M
Operating Income	-$34.64M	-$29.16M	-$42.03M	-$26.57M
EBITDA	-$33.45M	-$27.66M	-$40.14M	-$25.79M
Pretax Income	-$35.71M	-$29.49M	-$41.84M	-$26.26M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$35.71M	-$29.49M	-$41.84M	-$26.26M
Diluted EPS	-40.17	-24.83	-19.50	-6.33
Diluted Shares	888947	1.19M	3.38M	4.15M

TPST Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$31.23M	$39.23M	$30.27M	$7.71M
Receivables	$450.00K	$0.00	—	—
Current Assets	$32.95M	$40.36M	$31.47M	$8.27M
Total Assets	$46.09M	$51.60M	$41.49M	$16.93M
Current Liabilities	$7.28M	$9.41M	$14.22M	$3.31M
Long-Term Debt	$10.37M	$6.26M	—	—
Total Debt	$22.11M	$20.66M	$15.37M	$8.14M
Total Liabilities	$27.98M	$24.84M	$22.36M	$10.26M
Retained Earnings	-$135.77M	-$165.26M	-$207.11M	-$233.37M
Shareholders' Equity	$18.11M	$26.77M	$19.13M	$6.67M
Working Capital	$25.67M	$30.95M	$17.25M	$4.96M

TPST Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$31.07M	-$27.36M	-$33.03M	-$26.82M
Capital Expenditure	-$562.00K	-$170.00K	-$435.00K	—
Free Cash Flow	-$31.63M	-$27.53M	-$33.46M	-$26.82M
Depreciation & Amortisation	$638.00K	$381.00K	$389.00K	$266.00K
Stock-Based Compensation	$1.56M	$2.55M	$5.30M	$3.12M
Investing Cash Flow	-$562.00K	-$170.00K	-$435.00K	$0.00
Financing Cash Flow	$11.40M	$35.60M	$24.50M	$4.26M
Net Change in Cash	-$20.23M	$8.07M	-$8.96M	-$22.56M

TPST Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.63M	$3.87M	$570.00K	$539.00K	$22.29M
Selling, General & Admin	$3.31M	$4.09M	$3.03M	$3.54M	$5.42M
Operating Expenses	$10.94M	$7.97M	$3.60M	$4.08M	$27.72M
Operating Income	-$10.94M	-$7.97M	-$3.60M	-$4.08M	-$27.72M
EBITDA	-$10.63M	-$7.76M	-$3.44M	-$3.96M	-$27.64M
Pretax Income	-$10.86M	-$7.87M	-$3.51M	-$4.02M	-$27.70M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$10.86M	-$7.87M	-$3.51M	-$4.02M	-$27.70M
Diluted EPS	-41.08	-2.07	-0.79	—	-2.53
Diluted Shares	3.52M	3.80M	4.44M	—	10.93M

TPST Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$21.51M	$14.28M	$7.51M	$7.71M	$1.80M
Current Assets	$22.43M	$15.10M	$8.10M	$8.27M	$2.45M
Total Assets	$32.16M	$24.48M	$17.13M	$16.93M	$10.75M
Current Liabilities	$13.18M	$7.14M	$3.52M	$3.31M	$3.31M
Total Debt	$13.11M	$8.66M	$8.40M	$8.14M	$7.85M
Total Liabilities	$21.03M	$14.70M	$10.78M	$10.26M	$9.93M
Retained Earnings	-$217.97M	-$225.84M	-$229.35M	-$233.37M	-$270.07M
Shareholders' Equity	$11.13M	$9.78M	$6.35M	$6.67M	$822.00K
Working Capital	$9.26M	$7.96M	$4.58M	$4.96M	-$865.00K

TPST Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$8.04M	-$8.43M	-$6.78M	-$3.57M	-$7.60M
Free Cash Flow	-$8.04M	-$8.43M	-$6.78M	-$3.57M	-$7.60M
Depreciation & Amortisation	$68.00K	$67.00K	$66.00K	$65.00K	$60.00K
Stock-Based Compensation	$1.39M	$1.09M	$61.00K	$576.00K	$226.00K
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	-$721.00K	$1.20M	$13.00K	$3.77M	$1.70M
Net Change in Cash	-$8.76M	-$7.23M	-$6.77M	$193.00K	-$5.90M

Market Snapshot

About

Tempest Therapeutics is a clinical-stage biotechnology company developing cancer immunotherapy treatments. The company focuses on novel small molecule therapeutics targeting the tumor microenvironment to improve patient outcomes. Tempest is advancing multiple programs through clinical trials for various oncology indications.